Use of recombinant erythropoietins in the setting of renal disease
Author:
- 11 February 2006
- book chapter
- Published by Springer Nature
- p. 153-161
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Rheological studies during treatment of renal anaemia with recombinant human erythropoietinBritish Journal of Haematology, 2008
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in UremiaNew England Journal of Medicine, 1993
- Effect of Erythropoietin on Ischemia Tolerance in Anemic Hemodialysis Patients with Confirmed Coronary Artery DiseaseNephron, 1992
- Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patientsKidney International, 1991
- rHuEPO treatment improves brain and cognitive function of anemic dialysis patientsKidney International, 1991
- Coagulation Studies and Fistula Blood Flow During Erythropoietin Therapy in Haemodialysis PatientsNephrology Dialysis Transplantation, 1991
- Hemodynamic Changes in Hemodialyzed Patients during Treatment with Recombinant Human ErythropoietinNephron, 1991
- Impact of left ventricular hypertrophy on survival in end-stage renal diseaseKidney International, 1989
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987